Lauren Bullaro Riker Sells 1,150 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) SVP Lauren Bullaro Riker sold 1,150 shares of the firm’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $61.37, for a total transaction of $70,575.50. Following the completion of the transaction, the senior vice president now directly owns 14,002 shares of the company’s stock, valued at $859,302.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Lauren Bullaro Riker also recently made the following trade(s):

• On Thursday, March 10th, Lauren Bullaro Riker sold 9,300 shares of Pacira BioSciences stock. The shares were sold at an average price of $71.22, for a total transaction of $662,346.00.

Shares of PCRX traded down $2.95 during trading hours on Wednesday, reaching $59.39. 532,588 shares of the company traded hands, compared to its average volume of 525,248. The company has a current ratio of 2.19, a quick ratio of 1.85 and a debt-to-equity ratio of 1.03. The stock’s fifty day moving average price is $68.89 and its 200 day moving average price is $65.34. The firm has a market cap of $2.70 billion, a price-to-earnings ratio of 70.70 and a beta of 0.89. Pacira BioSciences, Inc. has a 12-month low of $45.05 and a 12-month high of $82.16.

Pacira BioSciences (NASDAQ:PCRX – Get Rating) last announced its earnings results on Wednesday, May 4th. The company reported $0.64 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.19). The firm had revenue of $157.99 million during the quarter, compared to the consensus estimate of $155.08 million. Pacira BioSciences had a return on equity of 15.17% and a net margin of 6.62%. The business’s revenue for the quarter was up 32.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.37 earnings per share. On average, research analysts forecast that Pacira BioSciences, Inc. will post 2.88 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in PCRX. UMB Bank N A MO increased its holdings in shares of Pacira BioSciences by 35.7% during the first quarter. UMB Bank N A MO now owns 566 shares of the company’s stock valued at $43,000 after acquiring an additional 149 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Pacira BioSciences by 1.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 9,684 shares of the company’s stock valued at $583,000 after acquiring an additional 174 shares in the last quarter. Van Hulzen Asset Management LLC increased its holdings in shares of Pacira BioSciences by 1.4% during the first quarter. Van Hulzen Asset Management LLC now owns 12,742 shares of the company’s stock valued at $972,000 after acquiring an additional 178 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Pacira BioSciences by 1.5% during the third quarter. Arizona State Retirement System now owns 11,992 shares of the company’s stock valued at $672,000 after acquiring an additional 183 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its holdings in shares of Pacira BioSciences by 0.9% during the fourth quarter. Louisiana State Employees Retirement System now owns 21,600 shares of the company’s stock valued at $1,300,000 after acquiring an additional 200 shares in the last quarter.

A number of research analysts recently weighed in on the stock. TheStreet lowered shares of Pacira BioSciences from a “b-” rating to a “c” rating in a report on Thursday, February 24th. Northland Securities raised their target price on shares of Pacira BioSciences from $61.00 to $67.00 in a report on Tuesday, March 1st. HC Wainwright raised their target price on shares of Pacira BioSciences from $86.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 25th. StockNews.com assumed coverage on shares of Pacira BioSciences in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Wedbush reissued a “buy” rating and issued a $94.00 target price (down from $97.00) on shares of Pacira BioSciences in a report on Saturday, February 26th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Pacira BioSciences has a consensus rating of “Buy” and a consensus price target of $80.63.

Pacira BioSciences Company Profile (Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

See Also